190 related articles for article (PubMed ID: 20628238)
21. Long-term maintenance treatment of moderate-to-severe plaque psoriasis with infliximab in combination with methotrexate or azathioprine in a retrospective cohort.
Dalaker M; Bonesrønning JH
J Eur Acad Dermatol Venereol; 2009 Mar; 23(3):277-82. PubMed ID: 19207642
[TBL] [Abstract][Full Text] [Related]
22. Successful treatment of hand and foot psoriasis with infliximab.
Di Lernia V; Guareschi E
Dermatol Online J; 2010 Jul; 16(7):8. PubMed ID: 20673536
[TBL] [Abstract][Full Text] [Related]
23. The impact of methodological approaches for presenting long-term clinical data on estimates of efficacy in psoriasis illustrated by three-year treatment data on infliximab.
Papoutsaki M; Talamonti M; Giunta A; Costanzo A; Ruzzetti M; Teoli M; Chimenti S
Dermatology; 2010; 221 Suppl 1():43-7. PubMed ID: 20733314
[TBL] [Abstract][Full Text] [Related]
24. Infliximab combined with methotrexate as long-term treatment for erythrodermic psoriasis.
Heikkilä H; Ranki A; Cajanus S; Karvonen SL
Arch Dermatol; 2005 Dec; 141(12):1607-10. PubMed ID: 16365275
[No Abstract] [Full Text] [Related]
25. [Our experience with infliximab in reclacitrant cases of psoriasis].
Pereiro M; González-Vilas D; Sánchez-Aguilar D; Toribio J
Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():43-7. PubMed ID: 19080991
[TBL] [Abstract][Full Text] [Related]
26. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis.
Menter A; Feldman SR; Weinstein GD; Papp K; Evans R; Guzzo C; Li S; Dooley LT; Arnold C; Gottlieb AB
J Am Acad Dermatol; 2007 Jan; 56(1):31.e1-15. PubMed ID: 17097378
[TBL] [Abstract][Full Text] [Related]
27. Infliximab (Remicade) for acute, severe pustular and erythrodermic psoriasis.
Lisby S; Gniadecki R
Acta Derm Venereol; 2004; 84(3):247-8. PubMed ID: 15202853
[No Abstract] [Full Text] [Related]
28. Programmed cell death of keratinocytes in infliximab-treated plaque-type psoriasis.
Krüger-Krasagakis S; Galanopoulos VK; Giannikaki L; Stefanidou M; Tosca AD
Br J Dermatol; 2006 Mar; 154(3):460-6. PubMed ID: 16445776
[TBL] [Abstract][Full Text] [Related]
29. Treatment of recalcitrant pustular psoriasis with infliximab: effective reduction of chemokine expression.
Benoit S; Toksoy A; Bröcker EB; Gillitzer R; Goebeler M
Br J Dermatol; 2004 May; 150(5):1009-12. PubMed ID: 15149518
[TBL] [Abstract][Full Text] [Related]
30. Infliximab efficacy in nail psoriasis. A retrospective study in 48 patients.
Fabroni C; Gori A; Troiano M; Prignano F; Lotti T
J Eur Acad Dermatol Venereol; 2011 May; 25(5):549-53. PubMed ID: 20707829
[TBL] [Abstract][Full Text] [Related]
31. Different response rates between palmoplantar involvement and diffuse plaque psoriasis in patients treated with infliximab.
Brunasso AM; Puntoni M; Delfino C; Massone C
Eur J Dermatol; 2012; 22(1):133-5. PubMed ID: 22134100
[No Abstract] [Full Text] [Related]
32. Infliximab monotherapy in psoriasis: a case of rapid clinical and histological response.
Vincek V; Jacob SE; Nassiri M; Herbert LM; Nadji M; Kerdel FA
Int J Dermatol; 2004 Apr; 43(4):303-8. PubMed ID: 15090021
[TBL] [Abstract][Full Text] [Related]
33. Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial.
Krueger GG; Langley RG; Finlay AY; Griffiths CE; Woolley JM; Lalla D; Jahreis A
Br J Dermatol; 2005 Dec; 153(6):1192-9. PubMed ID: 16307657
[TBL] [Abstract][Full Text] [Related]
34. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).
Antoni CE; Kavanaugh A; Kirkham B; Tutuncu Z; Burmester GR; Schneider U; Furst DE; Molitor J; Keystone E; Gladman D; Manger B; Wassenberg S; Weier R; Wallace DJ; Weisman MH; Kalden JR; Smolen J
Arthritis Rheum; 2005 Apr; 52(4):1227-36. PubMed ID: 15818699
[TBL] [Abstract][Full Text] [Related]
35. New development in the treatment of psoriasis--infliximab.
Pietrzak A; Chodorowska G; Jazienicka I; Junak-Bojarska A; Roliński J
Ann Univ Mariae Curie Sklodowska Med; 2003; 58(1):322-7. PubMed ID: 15315008
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of infliximab for severe recalcitrant psoriasis after 6 weeks of treatment.
DE Oliveira JP; Levy A; Morel P; Guibal F
J Dermatol; 2008 Sep; 35(9):575-80. PubMed ID: 18837702
[TBL] [Abstract][Full Text] [Related]
37. Persistent expression of CD26/DPPIV after treatment with infliximab in psoriasis despite clinical improvement.
van Lingen RG; van Erp PE; Seyger MM; de Jong EM; de Boer-van Huizen RT; Driessen RJ; van de Kerkhof PC
Acta Derm Venereol; 2009; 89(5):518-20. PubMed ID: 19734982
[No Abstract] [Full Text] [Related]
38. [What are the objectives of moderate to severe psoriasis treatment?].
Ortonne JP
Ann Dermatol Venereol; 2008 Jul; 135 Suppl 5():S281-4. PubMed ID: 18721665
[TBL] [Abstract][Full Text] [Related]
39. Brodalumab versus ustekinumab in psoriasis.
Fioranelli M; Roccia MG; Lotti T
Dermatol Ther; 2016 Sep; 29(5):298. PubMed ID: 26627075
[No Abstract] [Full Text] [Related]
40. Human immunodeficiency virus-associated psoriasis and psoriatic arthritis treated with infliximab.
Bartke U; Venten I; Kreuter A; Gubbay S; Altmeyer P; Brockmeyer NH
Br J Dermatol; 2004 Apr; 150(4):784-6. PubMed ID: 15099388
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]